FINWIRES · TerminalLIVE
FINWIRES

午间要闻：高盛股价下跌，尽管其第一季度盈利超出预期；Revolution公司胰腺癌药物达到关键研究目标

-- 周一上午交易时段，道琼斯工业平均指数下跌，而标普500指数和纳斯达克综合指数上涨。华尔街正在消化周末传来的消息：美国和伊朗未能达成协议，以及美国总统唐纳德·特朗普宣布封锁霍尔木兹海峡。 公司方面，高盛(GS)周一公布了第一季度财报，稀释后每股收益为17.55美元，高于去年同期的14.12美元，也高于FactSet分析师一致预期的16.47美元。第一季度净营收为172.3亿美元，高于去年同期的150.6亿美元，也高于FactSet一致预期的169.9亿美元。据彭博社援引知情人士消息报道，高盛还表示将在美国发行三期投资级债券，债券期限为4至8年。高盛股价在午盘前后下跌3.6%。 Revolution Medicines (RVMD) 周一表示，其用于治疗一种胰腺癌的实验性药物 daraxonrasib 的三期临床试验已达到关键目标。该公司称，该药物使患者的中位总生存期达到 13.2 个月，而化疗患者的中位总生存期为 6.7 个月。Revolution 表示，计划将相关数据提交给包括美国食品药品监督管理局 (FDA) 在内的全球监管机构，以申请上市许可。Revolution 股价上涨 36.4%。 GFL Environmental (GFL) 和 Secure Waste Infrastructure 周一宣布，双方已达成最终协议，将以每股 24.75 加元的价格收购 Secure Waste Infrastructure 的所有已发行和流通股，企业价值约为 64 亿加元（46.2 亿美元）。两家公司表示，该交易预计将于下半年完成。GFL 股价下跌 7.8%。 Fastenal (FAST) 周一公布了第一季度财报，稀释后每股收益为 0.30 美元，高于去年同期的 0.26 美元，与 FactSet 的预期一致。第一季度净销售额为22亿美元，高于去年同期的19.6亿美元，符合预期。Fastenal股价下跌6.7%。 康尼格拉食品公司（Conagra Brands，股票代码：CAG）周一宣布，已任命约翰·布雷斯（John Brase）为首席执行官兼总裁，该任命将于6月1日生效。布雷斯此前曾担任J.M. Smucker公司（股票代码：SJM）的首席运营官兼总裁，他将接替肖恩·康诺利（Sean Connolly）的职位。康诺利将于5月31日卸任其领导职务和董事会席位。康尼格拉股价下跌5.6%，J.M. Smucker股价下跌2.7%。 据《The Information》周一援引微软公司声明报道，微软正在为其人工智能助手Copilot开发新功能，希望这些功能能使其更像OpenClaw。微软股价上涨2.3%。

Price: $874.99, Change: $-32.81, Percent Change: -3.61%

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB